This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Delving into the recent data published in JAMA Dermatology from the Phase 2 clinical trial of cendakimab in patients with atopic dermatitis
Ticker(s): BMYWho's the expert?
- Specializes in medical dermatoloqv, sexually transmitted diseases, genital dermatology,
and infectious diseases of the skin. - Interim Chairman of the Department of Dermatology at Mount Sinai
Beth Israel - Assistant Professor of Dermatology at the Icahn School of Medicine at Mount Sinai
- Director of the Adult Dermatology Consultation Service at Mount Sinai Beth Israel.
Interview Goalto discuss the current treatment landscape and the potential of cendakimab, an anti-IL-13 monoclonal antibody being developed by BMS for the treatment of atopic dermatitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
